BOEHRINGER-INGELHEIM
25.4.2018 13:32:12 CEST | Business Wire | Press release
Family-owned pharmaceutical company Boehringer Ingelheim today presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany. The company’s R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted). With a high percentage of first-in-class and breakthrough potential drug candidates, Boehringer Ingelheim continues the successful implementation of its R&D strategy.
Boehringer Ingelheim is committing more than €20 billion to Research & Development for human pharmaceuticals by 2025. In the past four years, the company received 14 regulatory approvals in several new indications, including four new molecular entities and four breakthrough designations by the US Food and Drug Administration.
“The most ambitious goal for researchers is to achieve a medical breakthrough for patients from our over 80 clinical and pre-clinical projects. Some 65% of our drug pipeline candidates already have breakthrough and/or first-in-class potential, and we aim for even more” said Dr Michel Pairet, Member of the Board of Managing Directors, responsible for Boehringer Ingelheim’s Innovation Unit, “Transcending disease boundaries is about looking at R&D with fresh eyes.”
To fulfil such aspirations, Boehringer Ingelheim embraces risks to dig deep into the mechanisms of diseases, to integrate the latest scientific and technological advances, and to work with the best partners to discover and deliver new medicines.
“Our worldwide team of 8,000 scientists, medical doctors and other contributors is truly motivated by our pipeline, its progress and what this could mean for patients.” commented Dr Christopher Corsico, Chief Medical Officer, Boehringer Ingelheim. “With ongoing work on a first-in-class inhibitor targeting inflammatory skin and bowel diseases, transformative oncology candidates, a promising schizophrenia prevention strategy and major indications for two of our blockbusters, Ofev® in lung fibrosis and Jardiance® in chronic kidney disease and chronic heart failure, we look forward to bringing years of health and improved quality of life to millions of people.”
To support and complement its own R&D, Boehringer Ingelheim is increasing the emphasis on external collaborations and expanding the community of innovation partners. The company currently works with over 70 innovative partners in universities, scientific institutions and biotech companies.
“Our long-lasting relationships with our partners are built on respect, empathy, trust and passion – values which foster an environment where synergies are realized, resulting in the potential for faster and better results.” said Dr Michel Pairet. “Our long-term, unwavering commitment to researching and developing new medicines will bring the transformative medicines that patients need.”
Highlights of Latest Boehringer Ingelheim Pipeline Progress
Immunology
In Immunology Boehringer Ingelheim’s IL-36 receptor inhibitor has the potential to transform the standard-of-care for patients with immune-mediated diseases.
BI 655130, a new biological entity and first-in-class IL-36 receptor antibody, has shown strong efficacy in early clinical testing with a single dose in patients affected by Generalized Pustular Psoriasis. These results support a broad potential in multiple inflammatory diseases.
Trials are underway in further immune-mediated diseases of the skin and intestine including Palmo-Plantar Pustulosis, Ulcerative Colitis, Crohn’s Disease, and other chronic inflammatory conditions.
Oncology
Boehringer Ingelheim is exploring therapies that target tumour cells directly in pathways so far ‘undrugged’. In Immune Oncology, the research teams are “turning up the heat on cancer” with therapies that activate the abilities of the patient’s own immune system and by bringing together smart and highly promising combinations of both types of therapies.
We are advancing combinations of immune-cell targeted therapies e.g. cancer vaccines, oncolytic viruses and T-cell engagers, as well as immunogenic cell death inducers such as our SMAC mimetic with BI 754091, a PD-1 checkpoint inhibitor.
In cancer cell directed projects, Boehringer Ingelheim’s oncology research portfolio includes more than 10 clinical-stage assets. We are working on new drug candidates in pathways such as KRAS, WNT and p53, and will move towards clinical trials for many of these in the next 12-24 months.
Central Nervous System
In CNS, Boehringer Ingelheim has expanded its PDE9 inhibition research programs to the prevention of relapse in schizophrenia and also in the prevention of first episode psychosis.
Boehringer Ingelheim’s research approach in CNS is taking a courageous “against the current” approach. The focus is on understanding how underlying malfunctions in brain circuitry manifest in specific symptoms and traits of mental illnesses. This is key to going beyond the current disease classifications which do not reflect the underlying disease mechanisms.
Boehringer Ingelheim investigates a range of mental disorders such as schizophrenia, Alzheimer’s disease and depression.
Fibrosis (Respiratory and Cardiometabolic Diseases)
Based on the pathophysiological and mechanistic parallels of fibrotic diseases, Boehringer Ingelheim is investigating its compound nintedanib in a wide spectrum of fibrosing Interstitial Lung Diseases (ILDs).
Two Phase III clinical trials are exploring the efficacy and safety of nintedanib (OFEV® ) in Systemic Sclerosis ILD (SSc-ILD) and Progressive Fibrosing ILD (PF-ILD). The SENSCIS study has completed enrolment and may end in December 2018. The INBUILD study is likely to complete enrolment in Q2 2018.
In NASH, another fibrotic disease affecting the liver, Boehringer Ingelheim applies its deep understanding of the metabolic, inflammatory and fibrotic components of the disease and is investigating a frontrunner compound, an AOC3 inhibitor, in a Phase II clinical trial.
Cardiometabolic Diseases
In Cardiometabolic diseases, Boehringer Ingelheim is building on the strength of the results of the EMPA-REG OUTCOME® trial to explore the potential benefits of empagliflozin (JARDIANCE®1 ) beyond diabetes. Boehringer Ingelheim is investigating the potential of empagliflozin to protect patients with and without diabetes from the risk of chronic kidney disease and chronic heart failure.
Phase III studies are underway investigating the effects of empagliflozin in patients with Chronic Kidney Disease (CKD) and in patients with Chronic Heart Failure (CHF). The EMPA-KIDNEY and EMPEROR HEART FAILURE studies are expected to read out between 2019 and 2020.
About Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com
1 Jardiance® is jointly marketed by Boehringer Ingelheim and Eli Lilly and Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180425005687/en/
Contact:
Boehringer Ingelheim Corporate Center GmbH
Dr. Reinhard Malin
Head
of Communications, Innovation Unit
Media + PR
Phone: +49 6132
77-90815
press@boehringer-ingelheim.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SPIE Awards $351,000 in Scholarships to 85 Students Shaping the Future of Optics and Photonics28.5.2026 20:15:00 CEST | Press release
Annual scholarship program builds foundation for photonics industry’s next generation SPIE, the international society of optics and photonics, announced awarding $351,000 in scholarships that will provide support to 85 SPIE Student Members studying optics, photonics, or a related field. The scholarships range from $3,000 to $11,000 and awardees are selected by the SPIE Scholarship Committee from a roster of applicants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528142502/en/ “I am deeply passionate about advancing the inclusion of women and other underrepresented groups in the fields of optics and photonics, which makes it especially meaningful to be recognized as a recipient,” said Alana Gonzales, who received a $10,000 Women in Optics Scholarship. “Being able to apply this scholarship toward tuition, fees, and essential academic expenses such as books and electronics will both ease the financial burden of the final
Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study28.5.2026 14:30:00 CEST | Press release
RLS-1496 is an investigational, first-in-class, disease-modifying, selective glutathione peroxidase 4 (GPX4) modulator that targets pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases, such as AK, and represents a novel drug category — Adaptive SenoTherapeutics In recognition of May as Skin Cancer Awareness Month, Rubedo is calling attention to the myths and facts surrounding AKs — and to the urgent need for a new generation of treatments that are effective without the side-effect burden of today's options Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States,
ExaGrid Wins 5 Industry Awards at Network Computing Awards 202628.5.2026 14:00:00 CEST | Press release
ExaGrid named “Company of the Year” for seventh year in a row ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that company was honored with five industry awards, including Air-gapped Ransomware Recovery Product of the Year, Bench Tested Product of the Year, Company of the Year, Data Protection Product of the Year, and the Storage Product of the Year during the Network Computing Awards ceremony, held in London on May 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528849813/en/ The ExaGrid team headed to the stage five times throughout the Network Computing Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Network Computing Awards. The Network Computing Awards are determined by public vote. The 2026 awards mark
Ardoq Launches AI-First Enterprise Architecture Platform28.5.2026 14:00:00 CEST | Press release
Custom Agents, Omnipresent AI Assistant, and AI Import Builder Automate an Estimated 40% of Routine EA Work; Tenneco Already Achieving 292% ROI on Ardoq AI Ardoq, named a 5x Leader in the Gartner® Magic Quadrant™ for Enterprise Architecture Tools, today launched its AI-first enterprise architecture (EA) platform. The release grounds every Ardoq AI output in customers' live architecture data and introduces a new generation of AI agents capable of automating an estimated 40% of routine EA work. Architects today are being asked to defend decisions that generic AI is generating in seconds. Application rationalization choices. ERP transformation roadmaps. AI governance reviews. The questions land on the architect's desk, but the analysis underneath increasingly comes from AI assistants that do not know the architecture. Generic agents reason on whatever document is in front of them, not on the live relationships between applications, dependencies, capabilities, and risks. Ask a generic LLM
European DataWarehouse Launches DealDox®, a Next-Generation Virtual Data Room Built specifically for the Securitisation Market28.5.2026 14:00:00 CEST | Press release
European DataWarehouse (EDW) announced today the launch of DealDox®, a secure virtual data room uniquely tailored to the needs of the securitisation and structured finance market. Developed in response to long‑standing challenges around transaction data and document management, DealDox provides a single, secure environment where all parties throughout the deal lifecycle can collaborate efficiently while maintaining high standards of security, governance, and regulatory alignment. DealDox enables the centralised management of transaction data and documentation, offering robust security, granular access controls, and clear audit trails. The platform integrates seamlessly with EDW’s existing regulatory reporting ecosystem, supporting smoother workflows from deal preparation through to disclosure and compliance. “As a market infrastructure, our role is to reduce complexity and make processes simpler and more transparent for all participants,” said Dr. Christian Thun, CEO of European DataWa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom